Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
A transplantable hepatocarcinoma of strain 2 guinea pigs was used as an experimental model for immunotherapy of cancer. 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose (TDNM) was found to be more effective in producing regression of transplantable line-10 tumours than 6,6'-di-O-mycoloyl-alpha,alpha-trehalose (TDM) when combined with 6-O-stearoyl muramyldipeptide (L18-MDP). TDNM showed potent antitumour activity in combination with synthetic lipid A of Escherichia coli (compound 506), but not with the lipid A analogues (GLA-59 and 60). As with the combination of MDP derivative and lipid A analogue, MDP derivatives conjugated with GLA-60 (GMD compounds) showed no tumour regression activity of line-10 cells in guinea-pigs.
Ishida
H
H
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Saiki
I
I
Saito
S
S
Hasegawa
A
A
Kiso
M
M
Azuma
I
I
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003311:Cord Factors / Q000008:administration & dosage; D006168:Guinea Pigs; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction
D000276:Adjuvants, Immunologic; D003311:Cord Factors; D008050:Lipid A; C056260:GLA 60; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide